Story perspectives

FDA Panel Rejects AstraZeneca Breast Cancer Drug, 56% Progression Cut

5/2/2026

Summary

AstraZeneca Rejected

The FDA advisory panel voted 6-3 against approving AstraZeneca’s oral breast-cancer drug camizestrant.
The Phase 3 SERENA-6 trial showed a 56% reduction in disease progression or death risk, but overall-survival data are still immature.
AstraZeneca said it will keep working with the FDA and remains confident in camizestrant.
Analysts warned the vote could hurt sentiment because the drug is part of AstraZeneca’s $80 billion 2030 sales target.

Summary

AstraZeneca Mixed Verdict

The Oncology Drug Advisory Committee approved AstraZeneca’s Truqap for metastatic prostate cancer and rejected camizestrant.
CEO Pascal Soriot said the company remains confident in camizestrant despite the vote.
Bernstein lowered AstraZeneca’s target price to 18,600 pence from 20,500 pence, citing limited upside after the vote.
Trial data showed camizestrant combined with other drugs achieved a median progression-free survival of 16 months versus 9.2 months for standard therapy.

1 of 2

AstraZeneca Rejected

The FDA advisory panel voted 6-3 against approving AstraZeneca’s oral breast-cancer drug camizestrant.
The Phase 3 SERENA-6 trial showed a 56% reduction in disease progression or death risk, but overall-survival data are still immature.
AstraZeneca said it will keep working with the FDA and remains confident in camizestrant.
Analysts warned the vote could hurt sentiment because the drug is part of AstraZeneca’s $80 billion 2030 sales target.

1 / 2